Laman Utama9VC • FRA
add
ATAI Life Sciences NV
Tutup sebelumnya
€1.23
Julat hari
€1.22 - €1.22
Julat tahun
€0.95 - €2.48
Permodalan pasaran
285.56J USD
Bilangan Purata
283.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | -5.00K | -127.78% |
Perbelanjaan pengendalian | 29.34J | -12.62% |
Pendapatan bersih | -38.96J | -112.98% |
Margin untung bersih | 779.16K | 866.72% |
Pendapatan bagi setiap syer | -0.24 | -100.00% |
EBITDA | -29.12J | 12.97% |
Kadar cukai berkesan | 1.81% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 62.33J | -65.23% |
Jumlah aset | 159.39J | -45.69% |
Jumlah liabiliti | 42.83J | -12.87% |
Jumlah ekuiti | 116.55J | — |
Syer tertunggak | 198.31J | — |
Harga kepada buku | 1.78 | — |
Pulangan pada aset | -41.11% | — |
Pulangan pada modal | -46.44% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -38.96J | -112.98% |
Tunai daripada operasi | -24.30J | -10.62% |
Tunai daripada pelaburan | 6.56J | 897.08% |
Tunai daripada pembiayaan | 154.00K | 101.82% |
Perubahan bersih dalam tunai | -17.46J | 44.50% |
Aliran tunai bebas | -1.72J | 86.74% |
Perihal
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Diasaskan
2018
Tapak web
Pekerja
54
